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herapy in Acute Coronary Syndromes
Meta-Analysis of Contemporary Randomized Clinical Trials
nthony A. Bavry, MD, MPH,* Dharam J. Kumbhani, MD, SM,† Andrew N. Rassi, MD,‡
eepak L. Bhatt, MD,* Arman T. Askari, MD*
leveland, Ohio; and Philadelphia, Pennsylvania
OBJECTIVES This study sought to systematically determine whether early invasive therapy improves survival and
reduces adverse cardiovascular events in the management of non–ST-segment elevation acute
coronary syndromes.
BACKGROUND Although early invasive therapy reduces recurrent unstable angina, the magnitude of benefit
on other important adverse outcomes is unknown.
METHODS Clinical trials that randomized non–ST-segment elevation acute coronary syndrome patients
to early invasive therapy versus a more conservative approach were included for analysis.
RESULTS In all there were 7 trials with 8,375 patients available for analysis. At a mean follow-up of 2
years, the incidence of all-cause mortality was 4.9% in the early invasive group, compared with
6.5% in the conservative group (risk ratio [RR]  0.75, 95% confidence interval [CI] 0.63 to
0.90, p  0.001), and at 1 month (RR  0.82, 95% CI 0.50 to 1.34, p  0.43). At 2 years
of follow-up, the incidence of nonfatal myocardial infarction was 7.6% in the invasive group,
versus 9.1% in the conservative group (RR  0.83, 95% CI 0.72 to 0.96, p  0.012), and at
1 month (RR 0.93, 95% CI 0.73 to 1.19, p 0.57). At a mean of 13 months of follow-up,
there was a reduction in rehospitalization for unstable angina (RR  0.69, 95% CI 0.65 to
0.74, p  0.0001).
CONCLUSIONS Managing non–ST-segment elevation acute coronary syndromes by early invasive therapy
improves long-term survival and reduces late myocardial infarction and rehospitalization for
unstable angina. (J Am Coll Cardiol 2006;48:1319–25) © 2006 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.050of Cardiology Foundation
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although early invasive therapy is recommended for non–ST-
egment elevation acute coronary syndromes (NSTE-ACS)
1), the use of this approach remains suboptimal among
ligible patients (2). This strategy reduces composite cardiac
utcomes, largely by decreasing recurrent unstable angina and
he need for subsequent rehospitalization and revascularization
3). Meta-analyses have reported that early invasive therapy
ncreases mortality and myocardial infarction during the index
ospitalization (4), although a modest reduction in mortality
ay emerge later (4–6). Moreover, the most recent trial on
his topic documented a 50% increased risk for myocardial
nfarction (p  0.005), with similar mortality 1 year after
ospitalization for the NSTE-ACS (p  0.97) (7). Because
dditional studies and prolonged follow-up of earlier trials have
ow been reported, we sought to perform an updated meta-
nalysis to determine the magnitude of benefit of early invasive
herapy on individual outcomes of mortality, myocardial in-
arction, and recurrent unstable angina.
From the *Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland,
hio; †Department of Internal Medicine, University of Pennsylvania, Philadelphia,
ennsylvania; and the ‡School of Medicine, Case Western Reserve University,
leveland, Ohio.m
Manuscript received April 5, 2006; revised manuscript received May 30, 2006,
ccepted June 6, 2006.ETHODS
iterature review. We conducted a computerized literature
earch of the Medline and Google Scholar databases for
andomized clinical trials in the English language from
990 to 2006 using the search terms early invasive therapy,
onservative therapy, unstable angina, non–ST-segment
levation myocardial infarction, and acute coronary syn-
rome. We also corresponded with experts in the field and
sed the Science Citation Index to cross-reference any
tudies that met our selection criteria.
election criteria. We selected studies that enrolled pa-
ients with a diagnosis of NSTE-ACS, and randomized
ndividuals to early invasive therapy versus a more conser-
ative approach. We required that glycoprotein IIb/IIIa
nhibitors and/or thienopyridines, and coronary stents were
vailable for use during percutaneous coronary intervention
PCI). We excluded studies that enrolled patients with
hronic stable angina or with ST-segment elevation myo-
ardial infarction, that used fibrinolytic agents, or that did
ot have reliable outcome data available.
nd points/data extraction. The primary end point was
ll-cause mortality. Secondary end points were nonfatal
yocardial infarction and recurrent unstable angina that
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Early Invasive Therapy October 3, 2006:1319–25esulted in rehospitalization. We included all myocardial
nfarctions from each trial, rather than attempting to apply
uniform definition of myocardial infarction across all the
tudies. We tabulated overall rates of revascularization at the
ime of follow-up. Baseline information was tabulated, such
s patient demographics, adjunctive medications, and the
roportion of patients who received glycoprotein IIb/IIIa
nhibitors and coronary stents. Three independent reviewers
D.J.K., A.N.R., and A.T.A.) tabulated each clinical out-
ome. Once an event occurred, that patient was censored
rom contributing to future similar outcomes. Discrepancies
ere resolved through a fourth reviewer (A.A.B.). The
otality of data (i.e., cumulative events up to the extent of
ollow-up in each trial) was used to assess all outcomes,
lthough restricted data (i.e., cumulative events up to a
pecific follow-up period) were used for subanalysis. Be-
ause some degree of invasive therapy and subsequent
evascularization will invariably occur among conservatively
reated patients both during the index hospitalization and
fter discharge, we performed a subanalysis on studies with
similar relative difference in use of revascularization
etween treatment arms at follow-up. We also performed
ubanalysis on studies based on the median time of
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CI  confidence interval
FRISC-II  Fragmin and Fast
Revascularization During
Instability in Coronary Disease
ICTUS  Invasive Versus Conservative
Treatment in Unstable Coronary
Syndromes Investigators
ISAR-COOL  Intracoronary Stenting With
Antithrombotic Regimen
Cooling Off
NSTE-ACS  non–ST-segment elevation acute
coronary syndrome
PCI  percutaneous coronary
intervention
RITA-3  Randomized Intervention Trial
of Unstable Angina
RR  risk ratio
TACTICS TIMI-18  Treat Angina With Aggrastat
and Determine the Cost of
Therapy With an Invasive or
Conservative
Strategy—Thrombolysis In
Myocardial Infarction
TRUCS  Treatment of Refractory
Unstable Angina in
Geographically Isolated Areas
Without Cardiac Surgery
VINO  Value of First Day Coronary
Angiography/Angioplasty in
Evolving Non–ST-Segment
Elevation Myocardial Infarctionngiography. Atatistical analysis. We used the intention-to-treat prin-
iple to calculate risks. The risk for an outcome was defined
s the number of cardiac events that occurred during clinical
ollow-up divided by the number of individuals randomized
o invasive therapy or to conservative therapy. Risk ratios
ere defined as the risk of an outcome among those who
eceived invasive therapy compared with the risk of the
utcome among those who received conservative therapy. A
antel-Haenszel model was used to calculate a summary
tatistic for each outcome. We assessed for heterogeneity
etween studies by computing the Q statistic and for
ublication bias by constructing a Begg funnel plot. Mean
ollow-up was weighted according to each individual trial’s
ample size. All p values were 2-tailed, with statistical
ignificance set at 0.05, and confidence intervals calculated
t the 95% level. Analyses were performed using STATA
oftware version 9.0. (Stata Corp., College Station, Texas).
ESULTS
aseline characteristics. A total of 13 studies were initially
dentified; 3 studies were excluded for being noncontempo-
ary (i.e., before the era of enhanced antiplatelet therapy and
oronary stents) (8–10), 2 were excluded because fibrino-
ytic agents were used (11,12), and 1 study was excluded
ecause patients had chronic stable angina (13). In all, there
ere 7 studies with 8,375 total patients that were included
or analysis (Table 1) (3,7,14–21). Follow-up ranged from 1
onth (ISAR-COOL [Intracoronary Stenting With Anti-
hrombotic Regimen Cooling Off]) to 60 months (RITA-3
Randomized Intervention Trial of Unstable Angina]), and
of the 7 studies have reported outcomes beyond 1 year.
he weighted mean follow-up was 23.7 months. Complete-
ess of follow-up ranged from 98.8% to 100%. All partici-
ants received aspirin and either unfractionated or low-
olecular-weight heparin. Glycoprotein IIb/IIIa inhibitors
ere available during PCI in all trials except for VINO
Value of First Day Coronary Angiography/Angioplasty in
volving Non–ST-Segment Elevation Myocardial Infarc-
ion), and during medical stabilization in TACTICS
IMI-18 (Treat Angina With Aggrastat and Determine
he Cost of Therapy With an Invasive or Conservative
trategy—Thrombolysis In Myocardial Infarction) and
SAR-COOL. Thienopyridines were used as an adjunct to
CI in all trials.
Invasively treated patients were directed to catheteriza-
ion laboratories, and depending on coronary anatomy,
ontinued medical therapy or underwent revascularization
either by PCI or coronary artery bypass grafting [CABG]).
onservatively treated patients were generally managed
ith antiplatelet and antithrombin agents, and only directed
o catheterization laboratories if there were persistent angi-
al symptoms despite maximal medical therapy, if there
ere hemodynamic or electrical instability, or if a large
schemic burden was shown on predischarge stress testing.
notable exception to this approach was the ISAR-COOL
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October 3, 2006:1319–25 Early Invasive Therapyrial, in which diagnostic catheterization was performed
arly (i.e., within 6 h) or delayed (i.e., within 3 to 5 days).
ver the mean follow-up of 23.7 months, 71.1% of inva-
ively treated patients eventually underwent revasculariza-
ion by PCI or CABG, compared with 46.4% of conserva-
ively treated patients.
igure 1. Relative risk of all-cause mortality for early invasive therapy
ompared with conservative therapy at a mean follow-up of 2 years. The
esults show a long-term survival benefit from early invasive therapy. CI 
onfidence interval; FRISC-II  Fragmin and Fast Revascularization
uring Instability in Coronary Disease; ICTUS  Invasive Versus
onservative Treatment in Unstable Coronary Syndromes Investigators;
SAR-COOL  Intracoronary Stenting With Antithrombotic Regimen
ooling Off; RITA-3  Randomized Intervention Trial of Unstable
ngina; RR  relative risk; TIMI-18  Thrombolysis In Myocardial
nfarction-18; TRUCS  Treatment of Refractory Unstable Angina in
eographically Isolated Areas Without Cardiac Surgery; VINO  Value
able 1. Baseline Characteristics and Rates of Revascularization o
Characteristic FRISC-II TRUCS
nrollment period 1996–1998 1997–1998
nvasive/conservative patients, n 1222/1234 76/72
ge, yrs (mean) 66* 62
omen, % 30 27
iabetes, % 12 29
rior myocardial infarction, % 22 27†
urrent smokers, % 30 31
tatin at randomization, % 10 21
tatin at follow-up, % 55 NA
hienopyridine with PCI, % 100§ NA
levated troponin at randomization, % 55 NA
ours to angiography, median** 96/408 48/120††
lycoprotein IIb/IIIa inhibitor, type NA NA
Invasive undergoing PCI, % 10 95
Conservative undergoing PCI, % NA 96
Conservative not undergoing PCI, % NA NA
oronary stent use with PCI, %** 62/69 85/85
verall PCI or CABG, %** 78/45 100/61
elative difference in revascularization
between treatment arms, %
73 64
Median age. †Defined by prior PCI or CABG. ‡Defined as lipid-lowering therapy. §
By protocol, patients in both study arms received continuous tirofiban and daily
lopidogrel for 4 weeks. These agents were discontinued if PCI was not indicated. P
t discharge, clopidogrel was used in 61% of invasively treated patients, and 49% o
ormatted as invasive arm/conservative arm. ††Protocol required that patients under
CABG  coronary artery bypass grafting; NA  not available; PCI  percutanef First Day Coronary Angiography/Angioplasty in Evolving Non–ST-
egment Elevation Myocardial Infarction.
a
ill-cause mortality. For the primary outcome of all-cause
ortality, the weighted mean follow-up was 23.7 months.
mong patients randomized to early invasive therapy com-
ared with a more conservative approach, the mortality
ncidence was 4.9% versus 6.5% (risk ratio [RR]  0.75,
5% confidence interval [CI] 0.63 to 0.90, p  0.001)
Fig. 1). The number needed to treat with early invasive
herapy to save 1 life was 62 patients (p 0.001). There was
o evidence for heterogeneity among the studies (chi-square
6 degrees of freedom] 7.38, p  0.29) or publication bias
p  0.26). When the analysis was restricted to specific
ollow-up periods, the RR for mortality at 1 month was 0.82
95% CI 0.50 to 1.34, p  0.43); at 6 months 0.83 (95% CI
.63 to 1.09, p  0.19); at 12 months 0.80 (95% CI 0.61 to
igure 2. Relative risk of all-cause mortality for early invasive therapy
ompared with conservative therapy as a function of time. The results show
Study Participants
I-18 VINO RITA-3 ISAR-COOL ICTUS
7–1999 1998–2000 1997–2001 2000–2002 2001–2003
4/1106 64/67 895/915 203/207 604/596
62 66 62 70* 62*
34 39 38 33 27
28 25 13 29 14
39 26 28 23 23
A NA 32 21 41
52‡ 43‡ 45 NA 27
A NA 80 85 92
A 100§ 96 100¶ 100
54 100 75 67 100
2/79 6.2/1,464 48/1,020 2.4/86 23/283‡‡
ofiban NA NA Tirofiban Abciximab
94 0 25 100¶ 93
59 0 25 100¶ 69
99 0 0 100¶ 0
3/86 44/50 88/90 87/92 88/88
4/45 73/39 61/38 78/72 79/54
42 87 61 8 46
otocol, patients who received a stent were treated with a thienopyridine for 1 month.
grel (after a 600-mg loading dose) until PCI, followed by tirofiban for 24 h and
in both study arms initially received daily clopidogrel (after a 300-mg loading dose).
ervatively treated patients reflecting those who were not revascularized. **Data are
asive therapy within these times. ‡‡Median time until PCI, in hours.
ronary intervention.f the
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n early adverse events.
1
0
a
U
t
2
s
i
R
W
t
r
3
2
(
a
m
t
p
r
b
3
p
r
2
r
s
b
b
0
d
s
C
N
t
T
i
n
o
s
o
0
i
p
b
t
i
f
g
I
d
s
w
p
p
F
a
o go re
F
i
1322 Bavry et al. JACC Vol. 48, No. 7, 2006
Early Invasive Therapy October 3, 2006:1319–25.06, p  0.12); and at more than 24 months 0.75 (95% CI
.61 to 0.92, p  0.006) (Fig. 2).
There were 4 studies (TIMI-18, VINO, ISAR-COOL,
nd ICTUS [Invasive Versus Conservative Treatment in
nstable Coronary Syndromes Investigators]) with 3,961 pa-
ients that performed early invasive therapy on average within
4 h (weighted median time to angiography of 9.3 h) and 3
tudies (FRISC-II [Fragmin and Fast Revascularization Dur-
ng Instability in Coronary Disease], TRUCS [Treatment of
efractory Unstable Angina in Geographically Isolated Areas
ithout Cardiac Surgery], and RITA-3) with 4,414 patients
hat performed early invasive therapy more than 24 h after
andomization (weighted median time to angiography of
9.4 h).When early invasive therapy was performed more than
4 h after randomization, there was a reduction in mortality
RR 0.73, 95% CI 0.60 to 0.89, p 0.002); however, when
ngiography was performed within 24 h there was no incre-
ental improvement in this benefit (RR 0.82, 95% CI 0.57
o 1.16, p  0.26) (Fig. 3).
In 2 studies (TIMI-18 and ISAR-COOL, with 2,630
atients) there was a relatively small difference in the use of
evascularization (PCI or CABG) at the extent of follow-up
etween the treatment arms (Table 1). Similarly, there were
studies (TRUCS, RITA-3, and ICTUS, with 3,158
atients) with an intermediate difference in the use of
evascularization, and 2 studies (FRISC-II and VINO, with
,587 patients) with a relatively large difference in the use of
evascularization between treatment arms (Table 1). Among
tudies with a small difference in the use of revascularization
etween treatment arms, there was no obvious mortality
enefit from early invasive therapy (RR  0.88, 95% CI
.57 to 1.35, p  0.55); however, when there was a large
ifference in the use of revascularization, there was a
ignificant reduction in all-cause mortality (RR 0.63, 95%
I 0.44 to 0.89, p  0.01) (Fig. 3).
onfatal myocardial infarction. All trials reported nonfa-
al myocardial infarction as separate events, except for
igure 3. Relative risk of all-cause mortality based on time of angiograph
median of 9.3 h does not provide a greater survival advantage compared
f invasively treated patients relative to conservatively treated patients underIMI-18, which reported fatal and nonfatal myocardial
o
fnfarction as a composite event. The cumulative incidence of
onfatal myocardial infarctions was 7.6% among recipients
f early invasive therapy compared with 9.1% among con-
ervatively treated patients over a weighted mean follow-up
f 23.7 months (RR  0.83, 95% CI 0.72 to 0.96, p 
.012) (Fig. 4). The number needed to treat with early
nvasive therapy to prevent 1 myocardial infarction was 66
atients (p  0.011). There was no evidence for publication
ias (p  0.99), although there was excess heterogeneity
hat was caused by increased postprocedural myocardial
nfarction in the ICTUS trial (chi-square [6 degrees of
reedom] 21.30, p  0.002). There was no longer hetero-
eneity when only spontaneous myocardial infarction in the
CTUS trial was analyzed (chi-square [6 degrees of free-
om] 3.88, p  0.69). When the analysis was restricted to
pecific follow-up periods, the risk for myocardial infarction
as similar at 1 month (RR  0.93, 95% CI 0.73 to 1.19,
 0.57), at 6 months (RR  0.90, 95% CI 0.76 to 1.06,
 0.20), and at 12 months (RR  0.95, 95% CI 0.80 to
the extent of revascularization. The results show that invasive therapy at
angiography at a median of 39.4 h. In contrast, when a large proportion
vascularization by follow-up, there is a strong improvement in late survival.
igure 4. Relative risk of recurrent nonfatal myocardial infarction for early
nvasive therapy compared with conservative therapy at a mean follow-upy and
withf 2 years. The results show a long-term reduction in myocardial infarction
rom early invasive therapy. Abbreviations as in Figure 1.
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October 3, 2006:1319–25 Early Invasive Therapy.12, p  0.53), and was reduced at more than 24 months
f follow-up (RR  0.77, 95% CI 0.63 to 0.92, p  0.007).
ecurrent unstable angina requiring rehospitalization. For
he outcome of recurrent unstable angina requiring rehos-
italization, the weighted mean follow-up was 13.2 months.
his outcome occurred in 19.9% of individuals who received
arly invasive therapy, compared with 28.7% of conserva-
ively treated patients (RR  0.69, 95% CI 0.65 to 0.74,
 0.0001) (Fig. 5). The number needed to treat with early
nvasive therapy to prevent 1 rehospitalization for unstable
ngina was 11 patients (p 0.0001). There was no evidence
or heterogeneity among the studies (chi-square [5 degrees
f freedom] 3.95; p  0.56) or publication bias (p  0.71).
ISCUSSION
ur analysis of 7 contemporary randomized trials in over
,000 NSTE-ACS patients treated in the era of potent
ntiplatelet therapy and coronary stents shows that early
nvasive therapy decreases mortality by 25% at a mean of 2
ears of follow-up, compared with a more conservative
pproach. To save 1 life, 62 patients need to be treated with
arly invasive therapy. Early invasive therapy also decreases
onfatal myocardial infarction by 17% and recurrent unsta-
le angina requiring rehospitalization by 31%. To prevent 1
yocardial infarction, 66 patients need to be treated, and to
revent 1 future episode of rehospitalization for unstable
ngina, 11 patients need to be treated with this approach.
Trials that performed very early invasive therapy (median
f 9.3 h) did not show an improvement in long-term
urvival compared with trials that performed later angiog-
aphy (median of 39.4 h). The ISAR-COOL trial was the
nly trial in which both study arms underwent invasive
herapy, and this study found that very early angiography
median of 2.4 h) was superior to delayed angiography
median of 86 h); however, it is also possible that delaying
nvasive therapy for nearly 4 days with continuous glyco-
igure 5. Relative risk of recurrent unstable angina resulting in rehospi-
alization for early invasive therapy compared with conservative therapy at
mean follow-up of 13 months. The results show a long-term reduction in
ecurrent unstable angina from early invasive therapy. Abbreviations as in
igure 1.rotein IIb/IIIa inhibition could have been harmful (21). ilthough later angiography in our analysis was associated
ith improved survival, we would caution against purpose-
ully delaying invasive therapy because these trials were also
hose that revascularized a large proportion of early invasive
atients relative to conservatively treated patients. These
ndings suggest that revascularization may be the key
eterminant and not the timeliness of invasive therapy in
mproving late clinical outcomes. The goal in the manage-
ent of NSTE-ACS should be to perform early invasive
herapy within 48 h. This view is also supported by recent
nsight from the CRUSADE registry, in which a delay of
nvasive therapy of 46 h was not associated with increased
dverse events, compared with a delay of only 23 h (22).
The ICTUS trial documented a high incidence of post-
rocedural myocardial infarction, although this study used
he lowest threshold for defining (creatine kinase-MB
raction more than the upper limit of normal) and the
ighest frequency of sampling (every 6 h after PCI for 24 h)
or these events (7). Although this definition is consistent
ith the current consensus document of the joint European
ociety of Cardiology/American College of Cardiology
23), it is in contradistinction to the other trials, which
enerally only sampled blood once after PCI and defined a
ostprocedural myocardial infarction as a creatine
inase-MB 1.5 to 5 times the upper limit of normal. It is
ossible that the other trials in this analysis would have also
ocumented the same finding had they used a similar
hreshold and frequency for detecting such events. The
ignificance of increased postprocedural events has been
ontroversial (24,25), although an analysis of over 14,000
STE-ACS patients showed that spontaneous myocardial
nfarction is associated with a 6% to 8% higher absolute
ortality compared with postprocedural myocardial infarc-
ion (26). The FRISC-II trial also showed that over the
ong term, the benefit of revascularization seems to out-
eigh any early harmful effects. In this trial, mortality and
yocardial infarction were both significantly reduced at 1
ear from early invasive therapy despite a small excess in
arly myocardial infarctions (14).
The results of the ICTUS trial may have moved some
ractitioners to a state of uncertainty in regard to the
ptimal treatment of NSTE-ACS (7). In fact, an accom-
anying editorial to this trial suggested that the current
merican College of Cardiology/American Heart Associa-
ion and European Society of Cardiology guidelines may
eed to be challenged (27). This position should be tem-
ered by the current meta-analysis, which provides solid
vidence that early invasive therapy results in a long-term
urvival advantage without early harm.
A strength of this study is that it reflects current practice.
nalysis of noncontemporary trials performed before the era
f potent antiplatelet therapies and coronary stents showed
hat early invasive therapy was associated with harm (5).
lycoprotein IIb/IIIa inhibitors and stents enhance the
afety of PCI by decreasing major adverse cardiac events,
ncluding myocardial infarction and death (28–30). Addi-
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Early Invasive Therapy October 3, 2006:1319–25ionally, a meta-regression identified glycoprotein IIb/IIIa
nhibitors and stents to be the most significant predictors of
vent-free survival among invasively treated NSTE-ACS
atients (31). Other concerns exist with noncontemporary
rials such as VANQWISH (Veterans Affairs Non-QWave
nfarction Strategies In Hospital), in which the use of
eparin, beta-blockers, angiotensin-converting-enzyme in-
ibitors, and lipid-lowering therapies were encouraged, but
ot required (10), and in TIMI IIIb, in which half of the
articipants received tissue plasminogen activator (8), al-
hough fibrinolytic agents are now contraindicated in this
opulation (1). Accordingly, for a meta-analysis to be
elevant and guide management decisions, the studies that
re included for analysis should reflect current practice (32).
The optimized medical management that conservatively
reated patients received in the ICTUS trial needs to be
mphasized. By discharge, 94% of conservatively treated
atients were taking a statin, and 49% were taking clopi-
ogrel. Both of these therapies have been shown to reduce
omposite cardiac outcomes, including mortality, in the
anagement of NSTE-ACS (33–36). Although the current
ody of evidence clearly supports early invasive therapy in
he management of NSTE-ACS, future research is needed
o more precisely determine the optimal timing of this
pproach, the appropriate concomitant adjuvant therapy
hat is required, and whether additional risk stratification is
eeded before angiography is performed.
In summary, early invasive therapy in the management of
STE-ACS provides a durable survival advantage without
ncreasing early adverse events. This approach also reduces
onfatal myocardial infarction and recurrent unstable an-
ina requiring rehospitalization.
eprint requests and correspondence: Dr. Arman T. Askari, De-
artment of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid
venue, Desk F15, Cleveland, Ohio 44195. E-mail: askaria2@
cf.org.
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